PCA
KNSA icon

Pallas Capital Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Pallas Capital Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Sell
7,667
-49
-0.6% -$2.54K 0.02% 575
2026
Q1 		$372K Sell
7,716
-854
-10% -$37.8K 0.01% 584
2025
Q4 		$354K Buy
8,570
+30
+0.4% +$1.2K 0.01% 636
2025
Q3 		$332K Buy
8,540
+5
+0.1% +$162 0.01% 643
2025
Q2 		$236K Buy
+8,535
New +$217K 0.01% 720

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Pallas Capital Advisors's KNSA Position: Q2 2026 in Review

Pallas Capital Advisors reduced its Kiniksa Pharmaceuticals (KNSA) stake by 0.64% in Q2 2026, selling an estimated $2.54K and leaving 7,667 shares worth $490K. The position accounts for 0.02% of the portfolio, ranked #575.

Pallas Capital Advisors first reported a position in KNSA in Q2 2025 and has held it in 5 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Pallas Capital Advisors held 7,667 shares of Kiniksa Pharmaceuticals worth $490K as of Q2 2026.
  • Pallas Capital Advisors sold 49 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.54K.
  • Kiniksa Pharmaceuticals made up 0.02% of Pallas Capital Advisors's portfolio in Q2 2026, its #575 holding.
  • Pallas Capital Advisors first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.